Scarica l'app Stockscreener
2.33
1.27%
-0.03
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$2.36
Aprire:
$2.29
Volume 24 ore:
12,723
Relative Volume:
0.03
Capitalizzazione di mercato:
$5.91M
Reddito:
-
Utile/perdita netta:
$-9.64M
Rapporto P/E:
-0.3365
EPS:
-6.9236
Flusso di cassa netto:
$-10.11M
1 W Prestazione:
+1.30%
1M Prestazione:
+0.00%
6M Prestazione:
+10.77%
1 anno Prestazione:
-49.89%
Intervallo 1D:
$2.1136
$2.4463
Intervallo di 1 settimana:
$2.1006
$2.46
Portata 52W:
$1.72
$10.66
Gt Biopharma Inc Stock (GTBP) Company Profile
Nome
Gt Biopharma Inc
Settore
Industria
Telefono
(800) 304-9888
Indirizzo
315 MONTGOMERY STREET, SAN FRANCISCO
Confronta GTBP con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
| 0.2846 | 0 | 0 | 0 | 0 | 0.00 | |
GOODO
Gladstone Commercial Corporation
|
20.64 | 372.90M | 0 | 0 | 0 | 0.00 |
|
PSNYW
Polestar Automotive Holding Uk
|
0.1672 | 352.85M | 2.07B | -1.42B | -1.37B | -0.6765 |
|
MOBBW
Mobilicom Limited Warrants
|
0.34 | 278.60M | 0 | 0 | 0 | 0.00 |
|
JUNE
Dhandho Junoon Etf
|
11.05 | 144.42M | 0 | 0 | 0 | 0.00 |
|
SHMD
Schmid Group N V
|
3.20 | 137.80M | 0 | 0 | 0 | 0.00 |
Gt Biopharma Inc Stock (GTBP) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-12-02 | Iniziato | ROTH MKM | Buy |
| 2021-05-24 | Iniziato | H.C. Wainwright | Buy |
| 2021-04-13 | Iniziato | B. Riley Securities | Buy |
| 2021-03-17 | Iniziato | ROTH Capital | Buy |
Gt Biopharma Inc Borsa (GTBP) Ultime notizie
Biotech Stocks Are Tumbling — But The Top 5 Are Standouts - Investor's Business Daily
North American Morning Briefing : Stock Futures -2- - MarketScreener
GT Biopharma (GTBP) Projected to Post Quarterly Earnings on Tuesday - Defense World
Nanobodies Market Detailed In New Research Report 2025 | Sanofi, - openPR
The Goodyear Tire & Rubber Company (GT): A Bull Case Theory - Yahoo Finance
GT Biopharma to Participate in the 10th Anniversary of the Innate Killer Summit - GlobeNewswire
Can GT Biopharma's TriKE® Technology Transform Blood Cancer Treatment? Phase 1 Trial Updates Coming in 2025 - StockTitan
GT Biopharma Launches Shareholder Communications Initiative - ACCESS Newswire
Roth Capital Has Weak Forecast for GT Biopharma Q1 Earnings - Defense World
Analysts Issue Forecasts for GT Biopharma FY2029 Earnings - Defense World
GT Biopharma Announces Dosing Of New Patient In GTB-3550 TriKE(TM) Phase I/II Clinical Trial - ACCESS Newswire
GT Biopharma Announces $7.1 Million Convertible Debt Financing - ACCESS Newswire
GT Biopharma Retail Chatter Soars Most Among Biotechs After Financing Strategy Tweak - Asianet Newsable
GT Biopharma Announces Exercise of Warrants - GlobeNewswire
"Signal Advance, Inc. (OTC: SIGL) Achieves Technology - openPR
GT Biopharma announces warrant exercise, plans new offering - Investing.com India
GT Biopharma announces warrant exercise, plans new offering By Investing.com - Investing.com South Africa
GTBPGt Biopharma Inc Latest Stock News & Market Updates - StockTitan
Stock market today: Wah Fu Education Group +219.55%, Jet.AI +46.26% among top gainers in early trading - Business Upturn
Artificial Intelligence (AI) News Live Feed - StockTitan
GT Biopharma withdraws SEC registration statement - Investing.com India
GT Biopharma Announces Request for Withdrawal of Form S-1 Registration Statement - The Manila Times
GT Biopharma Pulls Back S-1 Filing: What Does This Mean for Their Financing Strategy? - StockTitan
GT Biopharma, Inc. SEC 10-K Report - TradingView
This New Nasdaq Biotech Could Revolutionize Emergency Cardiac CareHere's Why - StockTitan
Short Interest in GT Biopharma, Inc. (NASDAQ:GTBP) Expands By 5.1% - Defense World
Loss-Making Aytu BioPharma, Inc. (NASDAQ:AYTU) Set To Breakeven - Yahoo Finance
GT Biopharma Announces Recently Presented Data on Our Next Generation TriKE (OXS-C3550) at The Ash Meeting in Atlanta, GA - ACCESS Newswire
Nanobodies Market Analysis: Growth Drivers in Targeted - openPR
Pre-market Movers In Healthcare Sector: HUGE, ONTX, SVRA, CELC, CHFS... - RTTNews
StockNews.com Initiates Coverage on Beasley Broadcast Group (NASDAQ:BBGI) - Defense World
StockNews.com Begins Coverage on Ayala Pharmaceuticals (NASDAQ:ADXS) - Defense World
Barnes Group (NYSE:B) Now Covered by StockNews.com - Defense World
Apollo Commercial Real Estate Finance (NYSE:ARI) Stock Rating Lowered by StockNews.com - Defense World
KULR Technology Group Announces Strategic Partnership with EDOM Technology - Defense World
StockNews.com Begins Coverage on Power REIT (NYSE:PW) - Defense World
Evogene (NASDAQ:EVGN) Now Covered by Analysts at StockNews.com - Defense World
Embrace Change Acquisition Corp. Enters Definitive Merger Agreement with Tianji for Public ListingSAN DIEGO, CA – January 27, 2025 – Embrace Change Acquisition Corp. (NASDAQ: EMCGU), a special purpose acquisition company, and Tianji Tire Global - Defense World
Goldman Sachs Announces Adoption of Tax Benefit Preservation Plan - Defense World
First Financial Bancorp Reports Solid Financial Performance in Fourth Quarter 2024 - Defense World
Seaport Res Ptn Forecasts Weaker Earnings for Sands China - Defense World
Galectin Therapeutics Inc. Reports Results from 2024 Annual Meeting in Recent 8-K Filing - Defense World
Cormark Weighs in on Real Matters’ FY2025 Earnings (TSE:REA) - Defense World
AmpliTech Group, Inc. (NASDAQ:AMPG) Short Interest Down 60.9% in January - Defense World
GT Biopharma Announces First Patient Dosed in Phase 1 Trial - GlobeNewswire
GT Biopharma Announces Expanded TriKE(TM) Partnership With Cytovance Biologics - ACCESS Newswire
GT Biopharma, Inc. Announces First Patient Dosed in Phase 1 Trial of GTB-3650, Second-Generation TriKE for the Treatment of Hematologic Malignancies - Marketscreener.com
GT Biopharma Announces First Patient Dosed in Phase 1 Trial of GTB-3650, Second-Generation TriKE for the Treatment of Hematologic Malignancies - The Manila Times
GT Biopharma Initiates Phase 1 Trial of Advanced TriKE Therapy for Blood Cancers - StockTitan
GT Biopharma Provides Update Concerning Trike(TM) Drug Development Programs and Other Strategic Initiatives - ACCESS Newswire
GT Biopharma Announces Completion of $5.6 Million Bridge Financing - ACCESS Newswire
Gt Biopharma Inc Azioni (GTBP) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.23%
1.63%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):